FTT PET/CT in Metastatic Prostate Cancer (NCT05242744)
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Metastatic Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.
Who can join: Review the eligibility criteria below.
Location: University of Pennsylvania Hospital — Philadelphia, Pennsylvania
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Pennsylvania Hospital — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (215) 573-6569
Email: erin.schubert@pennmedicine.upenn.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer Metastatic
- REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer — New York, New York
- Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer — Duarte, California
- Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer — Victoria, British Columbia
- Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer — Baltimore, Maryland
- A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer — Duarte, California
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) — Orange, California
Explore by condition: All Prostate Cancer Metastatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.